Source:http://linkedlifedata.com/resource/pubmed/id/18095238
General Info
Abstract
This 52-week, randomized, double-blind, parallel-group study was designed to compare rosiglitazone/metformin fixed-dose combination therapy with combination sulphonylurea plus metformin therapy in overweight individuals with inadequately controlled type 2 diabetes mellitus.
PMID
18095238
Publication types
Comparative Study; Randomized Controlled Trial